drugset

drugset / Trial / NCT00092924

Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

NCT00092924 ↗

Phase 2 Completed Human Genome Sciences Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with relapsed or refractory non-small cell lung cancer.

Timeline

Start: —
Primary completion: 2005-01
Completion: 2005-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mapatumumab	Monoclonal antibody	—	—

Indications